Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review

Pharmacological Research

Volumn 61, Issue 6, 2010, Pages 473-481

  Repantis, Dimitris ^a   Laisney, Oona ^a   Heuser, Isabella ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acetylcholinesterase inhibitors; Cognitive enhancement; Memantine; Neuroenhancement; Neuroethics; Systematic review

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE;

ATTENTION; AVIATION; BEDTIME DOSAGE; BRAIN FUNCTION; CLINICAL TRIAL; COGNITION; DIZZINESS; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EMOTION; EPISODIC MEMORY; FLIGHT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMATION PROCESSING; INSOMNIA; MEMORY CONSOLIDATION; MOOD; MOTIVATION; NAUSEA; NIGHTMARE; OUTCOME ASSESSMENT; PERFORMANCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; QUALITY CONTROL; REVIEW; SINGLE DRUG DOSE; SLEEP DEPRIVATION; SOMNOLENCE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VERBAL MEMORY; VISUAL MEMORY; VOMITING; WAKEFULNESS;

CHOLINESTERASE INHIBITORS; COGNITION; EMOTIONS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; INDANS; MEMANTINE; MOTIVATION; PHENYLCARBAMATES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 77952874285     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.02.009     Document Type: Review

References (41)

1. Beglinger L.J., Gaydos B.L., Kareken D.A., Tangphao-Daniels O., Siemers E.R., Mohs R.C. Neuropsychological test performance in healthy volunteers before and after donepezil administration. J Psychopharmacol 2004, 18:102-108.
2. Beglinger L.J., Tangphao-Daniels O., Kareken D.A., Zhang L., Mohs R., Siemers E.R. Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study. J Clin Psychopharmacol 2005, 25:159-165.
3. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006, CD005593.
4. Chuah L.Y., Chee M.W. Cholinergic augmentation modulates visual task performance in sleep-deprived young adults. J Neurosci 2008, 28:11369-11377.
5. Chuah L.Y., Chong D.L., Chen A.K., Rekshan W.R., Tan J.C., Zheng H., et al. Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation. Sleep 2009, 32:999-1010.
6. de Jongh R., Bolt I., Schermer M., Olivier B. Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci Biobehav Rev 2008, 32:760-776.
7. Doran E., Henry D. Disease mongering: expanding the boundaries of treatable disease. Intern Med J 2008, 38:858-861.
8. Dumont G.J., de-Visser S.J., Cohen A.F., van-Gerven J.M. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Brit J Clin Pharmacol 2005, 59:495-510.
9. Farah M.J., Illes J., Cook-Deegan R., Gardner H., Kandel E., King P., et al. Neurocognitive enhancement: what can we do and what should we do?. Nat Rev Neurosci 2004, 5:421-425.
10. FitzGerald D.B., Crucian G.P., Mielke J.B., Shenal B.V., Burks D., Womack K.B., et al. Effects of donepezil on verbal memory after semantic processing in healthy older adults. Cogn Behav Neurol 2008, 21:57-64.
11. Galisteo M., Rissel M., Sergent O., Chevanne M., Cillard J., Guillouzo A., et al. Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation. J Pharmacol Exp Ther 2000, 294:160-167.
12. Greely H., Sahakian B., Harris J., Kessler R.C., Gazzaniga M., Campbell P., et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008, 456:702-705.
13. Gron G., Kirstein M., Thielscher A., Riepe M.W., Spitzer M. Cholinergic enhancement of episodic memory in healthy young adults. Psychopharmacology 2005, 182:170-179.
14. Harris J. Is it acceptable for people to take methylphenidate to enhance performance? Yes. BMJ 2009, 338:b1955.
15. Hart C.L., Haney M., Foltin R.W., Fischman M.W. Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology 2002, 164:376-384.
16. Hornung O.P., Regen F., Danker-Hopfe H., Schredl M., Heuser I. The relationship between REM sleep and memory consolidation in old age and effects of cholinergic medication. Biol Psychiatr 2007, 61:750-757.
17. Hutchison C.W., Nathan P.J., Mrazek L., Stough C. Cholinergic modulation of speed of early information processing: the effect of donepezil on inspection time. Psychopharmacology 2001, 155:440-442.
18. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials 1996, 17:1-12.
19. Korostenskaja M., Nikulin V.V., Kicic D., Nikulina A.V., Kahkonen S. Effects of NMDA receptor antagonist memantine on mismatch negativity. Brain Res Bull 2007, 72:275-283.
20. Lanni C., Lenzken S.C., Pascale A., Del Vecchio I., Racchi M., Pistoia F., et al. Cognition enhancers between treating and doping the mind. Pharmacol Res 2008, 57:196-213.
21. Larriviere D., Williams M.A., Rizzo M., Bonnie R.J. Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee. Neurology 2009, 73:1406-1412.
22. Maher B. Poll results: look who's doping. Nature 2008, 452:674-675.
23. McShane R., Areosa S.A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006, CD003154.
24. Morris K. Experts urge smart thinking on cognitive enhancers. Lancet Neurol 2008, 7:476-477.
25. Moynihan R., Heath I., Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002, 324:886-891.
26. Nathan P.J., Baker A., Carr E., Earle J., Jones M., Nieciecki M., et al. Cholinergic modulation of cognitive function in healthy subjects: acute effects of donepezil, a cholinesterase inhibitor. Hum Psychopharmacol Clin Exp 2001, 16:481-483.
27. Racchi M., Mazzucchelli M., Porrello E., Lanni C., Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004, 50:441-451.
28. Rammsayer T.H. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Neurobiol Learn Mem 2001, 8:20-25.
29. Rammsayer T.H. NMDA receptor activity and the transmission of sensory input into motor output in introverts and extraverts. Q J Exp Psychol B 2003, 56:207-221.
30. Rammsayer T.H. Effects of pharmacologically induced changes in NMDA receptor activity on human timing and sensorimotor performance. Brain Res 2006, 407-416.
31. Sahakian B., Morein-Zamir S. Professor's little helper. Nature 2007, 450:1157-1159.
32. Schöne-Seifert B., Talbot D. (Neuro-)Enhancement. Textbook of psychiatry 2010, Springer, New York. 2nd ed. H. Helmchen, N. Sartorius (Eds.).
33. Schugens M.M., Egerter R., Daum I., Schepelmann K., Klockgether T., Loschmann P.A. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neurosci Lett 1997, 224:57-60.
34. Snyder P.J., Bednar M.M., Cromer J.R., Maruff P. Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimer's Dementia 2005, 1:126-135.
35. Sonkusare S.K., Kaul C.L., Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res 2005, 51:1-17.
36. Spreen O., Strauss E. A compendium of neuropsychological tests; Administration, norms, and commentary 1998, Oxford University Press, Inc., New York. 2nd ed.
37. Swerdlow N.R., van Bergeijk D.P., Bergsma F., Weber E., Talledo J. The effects of memantine on prepulse inhibition. Neuropsychopharmacology 2009, 34:1854-1864.
38. Watkins P.B., Zimmerman H.J., Knapp M.J., Gracon S.I., Lewis K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271:992-998.
39. Wezenberg E., Verkes R.J., Sabbe B.G., Ruigt G.S., Hulstijn W. Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects. Psychopharmacology 2005, 181:582-594.
40. Yesavage J.A., Mumenthaler M.S., Taylor J.L., Friedman L., O'Hara R., Sheikh J., et al. Donepezil and flight simulator performance: effects on retention of complex skills. Neurology 2002, 59:123-125.
41. Zaninotto A.L., Bueno O.F., Pradella-Hallinan M., Tufik S., Rusted J., Stough C., et al. Acute cognitive effects of donepezil in young, healthy volunteers. Hum Psychopharmacol 2009, 24:453-464.